+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID05623267

Phase 23 Study of Sugemalimab vs Placebo as Consolidation Therapy for Limited-stage Small Cell Lung Cancer After Chemoradiotherapy

Led by Sun Yat-sen University · Updated on 2023-08-07

346

Participants Needed

1

Research Sites

65 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of sugemalimab as a consolidation therapy compared to a placebo in patients with limited-stage small cell lung cancer LS-SCLC who have not shown disease progression after completing concurrent or sequential chemoradiotherapy. This phase 23 randomized, double-blind, placebo-controlled study aims to assess the effectiveness of sugemalimab in this patient population, with progression-free survival as the primary outcome. Participants are randomly assigned in equal numbers to receive either sugemalimab or a placebo. Sugemalimab is given by intravenous infusion at a dose of 1200 mg on the first day of each treatment cycle, repeated every three weeks for up to one year or until disease progression or unacceptable side effects occur. The placebo arm follows the same schedule and administration method. Tumor response and minimal residual disease are monitored regularly using computed tomography or magnetic resonance imaging. Throughout the study, participants undergo tumor assessments every 12 weeks for the first two years, then every 24 weeks during the third year, and annually afterward until disease progression or death occurs. The study also measures overall survival, response rates, and disease control rates over up to 36 months. Participants health and response to treatment are closely monitored, and they are followed until disease progression or for the duration of the study period.

CONDITIONS

Brief Title

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Research Team

S

Shen Zhao, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here